Precigen, Inc. (PGEN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

18/25

Growth 5 Margin 5 Expansion 3 Platform 2 Financial 3

latest quarter score

Earnings Reports

18
PGEN Q2 2026: Pepsimius Revenue Surges 145% as Broad Label Drives Early Standard of Care Adoption
August 05, 2026
11
PGEN Q1 2026: Paximius Revenue Jumps 535% as Community Uptake Drives Launch Acceleration
May 14, 2026
13
PGEN Q4 2025: Pepsimios Launch Drives 149% Revenue Surge, RRP Market Adoption Accelerates
March 26, 2026
14
PGEN Q3 2025: Pepsimus Launch Engages 90% of Target Centers, Igniting Rare Disease Uptake Cycle
November 14, 2025
9
Precigen (PGEN) Q4 2024: PRGN-2012 Advances to FDA Priority Review with $98M Cash Runway Into 2026
March 19, 2025

Browse all companies